Search results for: S.R. Bornstein

Items from 1 to 20 out of 36 results

article

Most significant reduction of cardiovascular events in patients undergoing lipoproteinapheresis due to raised Lp(a) levels – A multicenter observational study

U. Schatz, S. Tselmin, G. Müller, U. Julius, more

Atherosclerosis Supplements > 2017 > 30 > C > 246-252

Lipoprotein(a) (Lp(a)) is an independent cardiovascular (CV) risk factor, predisposing to premature and progressive CV events. Lipoproteinapheresis (LA) is the only efficacious therapy for reducing Lp(a). Data comparing the clinical efficacy of LA with respect to reduction of CV events in subjects with elevated Lp(a) versus LDL-C versus both disorders is scarce. We aimed to perform this comparison...

article

Dysregulation of the CD4+ T cells lineage differentiation in dyslipidemic patients and impact of lipoprotein-apheresis treatment: A case study

J. Papin, A. Brennand, G. Arbore, B. Hohenstein, more

Atherosclerosis Supplements > 2017 > 30 > C > 238-245

Lipoprotein-apheresis (LA) is a therapeutic approach used against severe forms of dyslipidemia in patients who are non-responders or intolerant to pharmacological treatments. However, little is known about the potential pleiotropic effects of LA, particularly regarding the immune system and its regulation. Thus, in an attempt to analyse the potential effects of dyslipidemia and LA on the regulation...

article

Lipoprotein apheresis influences monocyte subpopulations

S. Jellinghaus, C. Reich, U. Schatz, S. Tselmin, more

Atherosclerosis Supplements > 2017 > 30 > C > 108-114

Monocytes can be differentiated into subpopulations depending on their expression profile of CD14 and CD16. CD16-positive monocytes are associated with coronary artery disease. Up to now, no data exist about the effect of lipoprotein apheresis (LA) on the distribution of monocyte subpopulations.80 patients who underwent LA at the University Hospital Dresden were included in the study. 8 out of the...

article

Kinetics of Lipoprotein(a) in patients undergoing weekly lipoprotein apheresis for Lp(a) hyperlipoproteinemia

S. Tselmin, G. Müller, U. Schatz, U. Julius, more

Atherosclerosis Supplements > 2017 > 30 > C > 209-216

Lipoprotein apheresis (LA) represents the only effective therapeutic option for patients with elevated Lipoprotein(a) (Lp(a)) levels. We aimed at analyzing the Lp(a) reduction, rebound rates as well as mean interval values between two weekly apheresis sessions, since this might be important for the prediction of the residual cardiovascular risk and development of individualized approaches for this...

article

Elevated lipoprotein(a) levels result in a high cardiovascular risk – A prospective analysis of a lipidology outpatients unit

U. Schatz, S. Fischer, U. Julius, S.R. Bornstein, more

Atherosclerosis > 2016 > 252 > C > e127-e128

article

TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients – A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose

U. Schatz, B.M.W. Illigens, T. Siepmann, B. Arneth, more

Atherosclerosis (Supplements) (Component) > 2015 > 18 > Complete > 199-208

Iron deficiency (ID) and iron deficiency anemia (IDA) are common findings in patients undergoing lipoprotein apheresis (LA). Different intravenous (iv) formulations are used to treat ID in LA patients, however guidelines and data on ID/IDA management in LA patients are lacking.We therefore performed a prospective observational multi-center cohort study of ID/IDA in LA patients, comparing two approved...

article

228: A novel animal model of phaeochromocytoma for preclinical therapy evaluation

M. Ullrich, R. Bergmann, J. Pietzsch, M. Cartellieri, more

European Journal of Cancer > 2014 > 50 > Supplement 5 > S53

article

Assessment of small fiber neuropathy to predict future risk of type 2 diabetes

G. Müller, E. Parfentyeva, J. Olschewsky, S.R. Bornstein, more

Primary Care Diabetes > 2013 > 7 > 4 > 269-273

Sudomotor dysfunction due to small fiber neuropathy can be observed very early in pre-diabetes. The aim of this study was to assess the predictive power of EZSCAN, a non invasive, quick and simple measurement of sudomotor function to identify glucose impairment.The study was performed in 76 German subjects at risk of diabetes. Glucose metabolism was assessed by using, oral glucose tolerance test (OGTT)...

article

Anti-tumor effects of peptide analogs targeting neuropeptide hormone receptors on mouse pheochromocytoma cells

C.G. Ziegler, M. Ullrich, A.V. Schally, R. Bergmann, more

Molecular and Cellular Endocrinology > 2013 > 371 > 1-2 > 189-194

Pheochromocytoma is a rare but potentially lethal chromaffin cell tumor with currently no effective treatment. Peptide hormone receptors are frequently overexpressed on endocrine tumor cells and can be specifically targeted by various anti-tumor peptide analogs. The present study carried out on mouse pheochromocytoma cells (MPCs) and a more aggressive mouse tumor tissue-derived (MTT) cell line revealed...

article

Iron deficiency and its management in patients undergoing lipoprotein apheresis. Comparison of two parenteral iron formulations

U. Schatz, B. Arneth, G. Siegert, D. Siegels, more

Atherosclerosis (Supplements) (Component) > 2013 > 14 > 1 > 115-122

There is evidence of iron deficiency (ID) in patients treated with lipoprotein apheresis. Aim of this study was to assess ID in apheresis patients and to study its management comparing safety and efficacy of two approved intravenous (i.v.) iron formulations.Inclusion criteria were defined as a) serum ferritin < 300 μg/l and transferrin saturation < 20%, b) ferritin < 100 μg/l. Both iron deficient...

article

Current situation of lipoprotein apheresis in Saxony

U. Julius, K. Taseva, S. Fischer, J. Passauer, more

Atherosclerosis (Supplements) (Component) > 2013 > 14 > 1 > 51-55

This paper summarizes the situation pertinent to treatment via lipoprotein apheresis in the federal state of Saxony, Germany in 2010. In total, 119 predominately male patients were treated in 10 centers; the majority of the patients was older than the mean age of the general population. Several risk factors were present, particularly a familial predisposition and hypertension. All patients had experienced...

article

Immunoadsorption for connective tissue disease

B. Hohenstein, S.R. Bornstein, M. Aringer

Atherosclerosis (Supplements) (Component) > 2013 > 14 > 1 > 185-189

Distinct connective tissue diseases (CTD's) such as systemic lupus erythematosus (SLE), systemic sclerosis, mixed connective tissue disease as well as dermato- and polymyositis comprise a group of diseases, where autoantibodies are not merely indicators of autoimmune disease, but also play an relevant role in the underlying pathogenicity. This knowledge led to the development of antibody targeting...

article

Lipoprotein apheresis reduces adipocyte fatty acid-binding protein serum levels

V. Lamounier-Zepter, C. Look, M. Ehrhart-Bornstein, S.R. Bornstein, more

Atherosclerosis (Supplements) (Component) > 2013 > 14 > 1 > 129-134

Adipocyte fatty acid-binding protein (FABP4) is a member of the intracellular lipid-binding protein family highly expressed in adipocytes and macrophages. Recent studies indicate a key role for circulating FABP4 in the pathogenesis of atherosclerosis and type 2 diabetes. We described an additional role for FABP4 in the development of cardiac dysfunction in obesity. Therefore, FABP4 seems to be a target...

article

Factors inducing cardiovascular events in patients treated by lipoprotein apheresis

K. Taseva, S. Fischer, J. Passauer, N. Weiss, more

Atherosclerosis (Supplements) (Component) > 2013 > 14 > 1 > 45-50

Lipoprotein apheresis is indicated in patients at high risk for cardiovascular disease due to severe hyperlipoproteinemia, which is not adequately controlled by diet and medication. This extracorporeal therapy reduces the event rate, although it does not completely abolish new events. We compared atherogenic risk factors in patients who were treated in 2009 and 2010 with lipoprotein apheresis and...

article

Regular lipoprotein apheresis maintains residual cardiovascular and microvascular function in patients with advanced atherosclerotic disease

M. Reimann, U. Julius, S.R. Bornstein, S. Fischer, more

Atherosclerosis (Supplements) (Component) > 2013 > 14 > 1 > 135-141

To determine whether previously demonstrated beneficial short-term effects on cardiovascular function in regular users of lipoprotein apheresis would be sustainable over time.Regular users of lipoprotein apheresis (n = 17) were studied between February 2009 and July 2010. All patients were examined for endothelial and autonomic function at baseline and at one year of regular treatment. Microvascular...

article

Differential effects of lipoprotein apheresis by lipidfiltration or dextran sulfate adsorption on lipidomic profile

J. Gräßler, S. Kopprasch, J. Passauer, S. Fischer, more

Atherosclerosis (Supplements) (Component) > 2013 > 14 > 1 > 151-155

Acute modification of plasma lipidomic profile was assessed by top-down shotgun profiling on a LTQ Orbitrap hybrid mass spectrometer in 14 patients treated with two different apheresis techniques: plasma lipidfiltration (LF) and whole blood dextran sulfate adsorption (DSA).Patients treated with DSA revealed a significantly more pronounced reduction of LDL-cholesterol (LDL-C), a diminished decrease...

article

Single whole blood dextran sulfate adsorption favorably affects systemic oxidative balance in lipoprotein apheresis patients

S. Kopprasch, S.R. Bornstein, P.E.H. Schwarz, S. Bergmann, more

Atherosclerosis (Supplements) (Component) > 2013 > 14 > 1 > 157-160

The acute changes of circulating oxidative stress parameters were compared in 16 patients undergoing two different apheresis techniques: plasma lipidfiltration (LF) or whole blood dextran sulfate adsorption (DSA).Immediately after apheresis LF was associated with an increase in systemic phagocyte count, enhanced formation of reactive oxygen species and decreased activity of the antioxidant enzyme...

article

Differences in the atherogenic risk of patients treated by lipoprotein apheresis according to their lipid pattern

M. von Dryander, S. Fischer, J. Passauer, G. Müller, more

Atherosclerosis (Supplements) (Component) > 2013 > 14 > 1 > 39-44

In high-risk patients who are already on a maximal lipid-lowering therapy, a lipoprotein apheresis is an important therapeutic option in preventing further progress of vascular complications as it may decrease both LDL-cholesterol (LDL-C) and lipoprotein(a) (Lp(a)) levels.We looked at the occurrence of cardiovascular events before apheresis and during apheresis in three groups defined by their lipid...

article

Nutzen und Risiken der modernen Pharmakotherapie des Typ-2-Diabetes

C. Schindler, A. Barthel, S. Fischer, S.R. Bornstein, more

Der Internist > 2012 > 53 > 4 > 478-487

Die Pharmakotherapie des Typ-2-Diabetes ist momentan eines der innovativsten Gebiete. Zahlreiche Neuentwicklungen waren in den vergangenen Jahren zu verzeichnen. Gleichzeitig ist aber gerade in diesem Bereich die Frage nach der Arzneimittelsicherheit immer wieder kontrovers diskutiert worden, weil sich gezeigt hat, dass die zum Zeitpunkt der Arzneimittelzulassung vorliegenden Daten offenbar nicht...

article

MS20 NATIVE AND GLYCOXIDIZED HIGH DENSITY LIPOPROTEIN (HDL) MODULATE ADRENAL STEROIDOGENESIS VIA SCAVENGER RECEPTOR CLASS B, TYPE I (SR-BI)

S. Kopprasch, S. Saha, J. Graessler, J. Pietzsch, more

Atherosclerosis (Supplements) (Component) > 2010 > 11 > 2 > 113

Publication date

Set your own date range

INFONA - science communication portal

Search results for: S.R. Bornstein

Most significant reduction of cardiovascular events in patients undergoing lipoproteinapheresis due to raised Lp(a) levels – A multicenter observational study

Dysregulation of the CD4+ T cells lineage differentiation in dyslipidemic patients and impact of lipoprotein-apheresis treatment: A case study

Lipoprotein apheresis influences monocyte subpopulations

Kinetics of Lipoprotein(a) in patients undergoing weekly lipoprotein apheresis for Lp(a) hyperlipoproteinemia

Elevated lipoprotein(a) levels result in a high cardiovascular risk – A prospective analysis of a lipidology outpatients unit

TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients – A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose

228: A novel animal model of phaeochromocytoma for preclinical therapy evaluation

Assessment of small fiber neuropathy to predict future risk of type 2 diabetes

Anti-tumor effects of peptide analogs targeting neuropeptide hormone receptors on mouse pheochromocytoma cells

Iron deficiency and its management in patients undergoing lipoprotein apheresis. Comparison of two parenteral iron formulations

Current situation of lipoprotein apheresis in Saxony

Immunoadsorption for connective tissue disease

Lipoprotein apheresis reduces adipocyte fatty acid-binding protein serum levels

Factors inducing cardiovascular events in patients treated by lipoprotein apheresis

Regular lipoprotein apheresis maintains residual cardiovascular and microvascular function in patients with advanced atherosclerotic disease

Differential effects of lipoprotein apheresis by lipidfiltration or dextran sulfate adsorption on lipidomic profile

Single whole blood dextran sulfate adsorption favorably affects systemic oxidative balance in lipoprotein apheresis patients

Differences in the atherogenic risk of patients treated by lipoprotein apheresis according to their lipid pattern

Nutzen und Risiken der modernen Pharmakotherapie des Typ-2-Diabetes

MS20 NATIVE AND GLYCOXIDIZED HIGH DENSITY LIPOPROTEIN (HDL) MODULATE ADRENAL STEROIDOGENESIS VIA SCAVENGER RECEPTOR CLASS B, TYPE I (SR-BI)

Filter options

Publication date

Content availability

Publication language

Keywords

Data set

Journal

INFONA - science communication portal

Search results for: S.R. Bornstein

Add recipient

Sending message cancelled

Are you sure you want to cancel sending this message?

Send message

Filter options

Publication date

Date range setting

Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.

Content availability

Publication language

Keywords

Data set

Journal

Reporting an error / abuse

Sending the report failed

Accessibility options